Evidence map›Paper›PMID 36241231›Full record

ArticleBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences2022

[Preclinical study of T cell receptor specifically reactive with

X J Cheng, D Jiang, L H Zhang, J H Wang, Y Z Li, J H Zhai, B Q Yan, L L Zhang, X W Xie, Z Y Li and 1 more

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. An Engineered Soluble Single-Chain TCR Engager for KRAS-G12V Specific Tumor Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

X J ChengDepartment of Gastrointestinal Cancer Center, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education; Laboratory of Genetics, Peking University Cancer Hospital & Institute, Beijing 100142, China.
D JiangBeijing CorreGene Biotechnology Co., Ltd., Beijing 100094, China.
L H ZhangDepartment of Gastrointestinal Cancer Center, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education; Laboratory of Genetics, Peking University Cancer Hospital & Institute, Beijing 100142, China.
J H WangBeijing CorreGene Biotechnology Co., Ltd., Beijing 100094, China.
Y Z LiBeijing CorreGene Biotechnology Co., Ltd., Beijing 100094, China.
J H ZhaiBeijing CorreGene Biotechnology Co., Ltd., Beijing 100094, China.
B Q YanBeijing CorreGene Biotechnology Co., Ltd., Beijing 100094, China.
L L ZhangBeijing CorreGene Biotechnology Co., Ltd., Beijing 100094, China.
X W XieBeijing CorreGene Biotechnology Co., Ltd., Beijing 100094, China.
Z Y LiDepartment of Gastrointestinal Cancer Center, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education; Laboratory of Genetics, Peking University Cancer Hospital & Institute, Beijing 100142, China.
J F JiDepartment of Gastrointestinal Cancer Center, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education; Laboratory of Genetics, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Beijing VDJBio (China) · CNMinistry of Education · ET

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objective

methodsIn this study, tumor infiltrating lymphocytes were obtained from one colorectal cancer patient carrying

resultsWe obtained a high-affinity TCR sequence that specifically recognized the HLA-A

conclusionKVA11-01 TCR-T cells can effectively target a variety of malignant tumor cells carrying

Indexed as

NeoplasmsProto-Oncogene Proteins p21(ras)AnimalsDNA, ComplementaryEpitopesHLA-A AntigensHumansInterferon-gammaMiceMice, NudeMutationReceptors, Antigen, T-CellDNA, ComplementaryEpitopesHLA-A AntigensInterferon-gammaKRAS protein, humanProto-Oncogene Proteins p21(ras)Receptors, Antigen, T-CellDNA mutational analysisNeoplasmsT-cell receptorTumor-infiltrating lymphocytes

Identifiers

PMID36241231
PMCPMC9568380
OpenAlexW4306316578

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.